TAT-10: Production of a Thorium/Actinium Generator at the Canadian Nuclear Laboratories
Kanazawa, Japan (UroToday.com) The Canadian Nuclear Laboratory (CNL) at Chalk River, Ontario has a stockpile of U233 which is used to construct a Thorium/Actinium generator for the production of Ac225. A Thorium fraction containing most the desired isotope Th229 has been isolated with anion exchange and chromatographic techniques.
TAT-10: Progress Toward an Alternate Method for Production of Ac-225
Kanazawa, Japan (Urotoday.com) Northstar Medical Radioisotopes, LLC is a commercial supplier of Mo99/Tc99m and is looking at potential procedures for large-scale production of Ac225. After examining several possible production paths, high-energy proton spallation was chosen for Th229 production. A proof-of-concept experiment was carried out using spare protons from Fermilab’s 8 GeV Booster accelerator. The company envisions banks of redundant Thorium/Actinium generators to reach commercial scale supplies of Ac225.
TAT-10: Radium 223 from Bench to Bedside, and Future Directions for Targeted Alpha Therapy
Kanazawa, Japan (UroToday.com) Dr. Joe O’Sullivan, a Professor of Radiation Oncology at Queen’s College, briefly reviewed the history of radiation treatment of cancer (and prostate cancer in particular) beginning with Radium treatment only eight years after its discovery by the Curies. A landmark paper on radioactive phosphorous treatment of bone-metastatic prostate cancer was published in the journal Lancet in 1964. More recent internal treatments have concentrated on calcium analogs that are directly absorbed in the bone tumor, starting with Sr98, a beta emitter. Single agent beta emitters showed some (~50 %) palliative response but no benefit for overall survival.